Literature DB >> 11912143

Simultaneous inhibition of the receptor kinase activity of vascular endothelial, fibroblast, and platelet-derived growth factors suppresses tumor growth and enhances tumor radiation response.

Robert J Griffin1, Brent W Williams, Robert Wild, Julie M Cherrington, Heonjoo Park, Chang W Song.   

Abstract

We have investigated the effect of simultaneous inhibition of multiple angiogenic growth factor signaling pathways on tumor growth, tumor blood perfusion, and radiation-induced tumor-growth delay using SU6668, an inhibitor of the receptor-tyrosine kinase activity of vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF), and platelet-derived growth factor (PDGF). The SCK mammary carcinoma, FSaII fibrosarcoma, and CFPAC human pancreatic carcinoma were grown s.c. in the hind leg of A/J mice, C3H mice, and Balb/cAnNCrl-nuBr nude mice, respectively. Daily i.p. injection of 100 mg/kg of SU6668 markedly suppressed the growth of these three tumor types. SU6668 also markedly prolonged the survival time of host mice bearing SCK tumors, which appeared to be caused by a reduction of metastatic tumor growth in the lung. There was little or no change in normal tissue blood perfusion, whereas in SCK tumors the perfusion decreased by 50% at 1 h after a single i.p. injection of SU6668, slightly recovered at 4 h, and completely recovered by 8 h. Interestingly, the tumor blood flow was significantly increased above the baseline level 24 h after SU6668 injection. After extended daily i.p. injections of SU6668, the tumor blood flow in all of the three tumor types studied was markedly decreased compared with control. The observed effects of this drug on tumor blood perfusion may partially explain the effectiveness of the compound in suppressing tumor growth and extending survival of tumor-bearing mice. We also observed that daily SU6668 administration and a single dose of 15 Gy of X-irradiation was significantly more effective than either treatment alone in suppressing tumor growth. Our results suggest that SU6668 increased the radiosensitivity of tumor blood vessels. We conclude that SU6668 is a potent therapeutic agent potentially useful to suppress tumor growth and enhance the response of tumors to radiotherapy.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11912143

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  38 in total

1.  Sequential loss of tumor vessel pericytes and endothelial cells after inhibition of platelet-derived growth factor B by selective aptamer AX102.

Authors:  Barbara Sennino; Beverly L Falcón; Dilara McCauley; Tom Le; Thomas McCauley; Jeffrey C Kurz; Amy Haskell; David M Epstein; Donald M McDonald
Journal:  Cancer Res       Date:  2007-08-01       Impact factor: 12.701

2.  Improved intratumoral oxygenation through vascular normalization increases glioma sensitivity to ionizing radiation.

Authors:  Mackenzie C McGee; J Blair Hamner; Regan F Williams; Shannon F Rosati; Thomas L Sims; Catherine Y Ng; M Waleed Gaber; Christopher Calabrese; Jianrong Wu; Amit C Nathwani; Christopher Duntsch; Thomas E Merchant; Andrew M Davidoff
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-04       Impact factor: 7.038

3.  The addition of Sunitinib to radiation delays tumor growth in a murine model of glioblastoma.

Authors:  Randy D'Amico; Liang Lei; Benjamin C Kennedy; Julia Sisti; Victoria Ebiana; Celina Crisman; James G Christensen; Orlando Gil; Steven S Rosenfeld; Peter Canoll; Jeffrey N Bruce
Journal:  Neurol Res       Date:  2012-03-05       Impact factor: 2.448

Review 4.  Could Perioperative Opioid Use Increase the Risk of Cancer Progression and Metastases?

Authors:  Anupam Aich; Pankaj Gupta; Kalpna Gupta
Journal:  Int Anesthesiol Clin       Date:  2016

5.  A phase 1b trial of the combination of the antiangiogenic agent sunitinib and radiation therapy for patients with primary and metastatic central nervous system malignancies.

Authors:  Evan J Wuthrick; Mitchell Kamrava; Walter J Curran; Maria Werner-Wasik; Kevin A Camphausen; Terry Hyslop; Rita Axelrod; David W Andrews; Jon Glass; Mitchell Machtay; Adam P Dicker
Journal:  Cancer       Date:  2011-06-03       Impact factor: 6.860

6.  Tumor-Endothelial Cell Three-dimensional Spheroids: New Aspects to Enhance Radiation and Drug Therapeutics.

Authors:  Meenakshi Upreti; Azemat Jamshidi-Parsian; Nathan A Koonce; Jessica S Webber; Sunil K Sharma; Alexzander Aa Asea; Mathew J Mader; Robert J Griffin
Journal:  Transl Oncol       Date:  2011-12-01       Impact factor: 4.243

7.  Spatially fractionated radiation induces cytotoxicity and changes in gene expression in bystander and radiation adjacent murine carcinoma cells.

Authors:  Rajalakshmi S Asur; Sunil Sharma; Ching-Wei Chang; Jose Penagaricano; Indira M Kommuru; Eduardo G Moros; Peter M Corry; Robert J Griffin
Journal:  Radiat Res       Date:  2012-05-04       Impact factor: 2.841

Review 8.  Combination of antiangiogenesis with chemotherapy for more effective cancer treatment.

Authors:  Jie Ma; David J Waxman
Journal:  Mol Cancer Ther       Date:  2008-12       Impact factor: 6.261

9.  Synergistic effect of ionizing radiation and beta-Lapachone against RKO human colon adenocarcinoma cells.

Authors:  Eun Jung Kim; In-Mi Ji; Ki-Jung Ahn; Eun Kyung Choi; Heon-Jin Park; Byung Uk Lim; Chang W Song; Heon Joo Park
Journal:  Cancer Res Treat       Date:  2005-06-30       Impact factor: 4.679

Review 10.  Gastrointestinal radiation injury: symptoms, risk factors and mechanisms.

Authors:  Abobakr K Shadad; Frank J Sullivan; Joseph D Martin; Laurence J Egan
Journal:  World J Gastroenterol       Date:  2013-01-14       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.